Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Otsuka ICU Medical LLCOtsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride InjectionContact: Consumers ICU Medical, Inc. 1-844-654-7780 — Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% SODIUM CHLORIDE Injection, USP, 100 mL single pack to the user level due to a potential mix-up. The affected lot of...
- Memorial Healthcare SystemJOE DIMAGGIO CHILDREN'S HOSPITAL NATIONALLY RANKED IN FIVE SPECIALTIES BY U.S. NEWS & WORLD REPORTJoe DiMaggio Children's Hospital at Memorial Healthcare System has once again been named one of U.S. News & World Report's 2026-2027 Best Children's Hospitals, earning top rankings in five pediatric specialties. "This recognition belongs to...
- Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by AstraZeneca for Etcamah™ (camizestrant), which is indicated for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, based on a US Food and Drug Administration (FDA)-authorized test.1
- Kaplan Fox & Kilsheimer LLPKaplan Fox Notifies Investors of Hims & Hers Health, Inc. (HIMS) of the Lead Plaintiff Deadline on November 2, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may...
- Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGNCompanies: BiogenBiogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology (CJASN). The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Society of Paediatric Nephrology (ESPN).
- Ayble Health, Inc./C O R R E C T I O N -- Ayble Health, Inc./In the news release, Ayble Health Raises $16M Series A to Expand the Nation's Most Clinically Validated Virtual Digestive Health Clinic, issued 16-Sep-2026 by Ayble Health, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release...
- Blue Shield of CaliforniaBLUE SHIELD OF CALIFORNIA EXPANDS VIRTUAL BLUE PROGRAM, BRINGING $0 OUT-OF-POCKET VIRTUAL CARE BENEFIT TO 260,000 MORE MEMBERSExpansion will more than double program enrollment; members get unlimited virtual primary, behavioral health, and specialist visits with $0 out-of-pocket costs and often same-day access. — Blue Shield of California today announced a...
- Alice L. Walton FoundationAlice L. Walton Foundation and Mercy Break Ground on AWSOM Whole Health Campus, Marking a New Era for Whole-Person Health in the HeartlandBuildings for world-class specialty care, including cardiac and cancer care, will anchor the first phase of a 120+-acre destination Key Points The Alice L. Walton Foundation and Mercy broke ground on a 120+-acre campus for specialty care and whole-health innovation in Bentonville,...
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruger & Company, Inc. (NYSE – RGR), Atkore, Inc. (NYSE – ATKR), Centerspace (NYSE – CSR), Aethlon Medical, Inc. (Nasdaq – AEMD)Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
- Faruqi & Faruqi LLPFaruqi & Faruqi, LLP Urges Hims & Hers Health, Inc. (HIMS) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class ActionFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Hims to Contact Him Directly to Discuss Their OptionsNew York, New York--(September 17, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE:...
- BetterLife Pharma Inc.BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded WarrantsBetterLife Pharma Inc. (CSE: BETR) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, is pleased to announce that it has closed its previously announced public offering (the "Offering") of common shares of the Company ("Common Shares") and pre-funded common share purchase warrants of the Company ("Pre-Funded Warrants" and, together with the Common Shares, the...
- National Comprehensive Cancer NetworkThere's No One-Size-Fits-All for Treating Older Adults with Cancer, According to New NCCN Patient ResourceNew guideline for patients and caregivers explains the importance of assessments to tailor cancer care to every person, regardless of age. — Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer...